Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 817 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 817 shares of the business’s stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $37.99, for a total value of $31,037.83. Following the transaction, the insider directly owned 83,698 shares of the company’s stock, valued at $3,179,687.02. The trade was a 0.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Castle Biosciences Stock Up 2.1%

CSTL stock traded up $0.68 during mid-day trading on Friday, reaching $33.08. The company had a trading volume of 150,839 shares, compared to its average volume of 395,539. The firm has a fifty day simple moving average of $39.51 and a 200 day simple moving average of $29.52. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.31 and a current ratio of 6.47. The company has a market capitalization of $965.43 million, a price-to-earnings ratio of -73.37 and a beta of 1.06. Castle Biosciences, Inc. has a fifty-two week low of $14.59 and a fifty-two week high of $44.28.

Castle Biosciences (NASDAQ:CSTL) last released its earnings results on Monday, November 3rd. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.32. Castle Biosciences had a negative net margin of 3.56% and a positive return on equity of 1.73%. The firm had revenue of $80.55 million for the quarter, compared to analyst estimates of $71.06 million. Analysts forecast that Castle Biosciences, Inc. will post 0.44 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on CSTL shares. Lake Street Capital lifted their price objective on shares of Castle Biosciences from $35.00 to $52.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. BTIG Research lifted their price target on Castle Biosciences from $38.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Canaccord Genuity Group increased their price objective on Castle Biosciences from $37.00 to $50.00 and gave the company a “buy” rating in a report on Monday, December 22nd. Zacks Research upgraded Castle Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Monday. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Castle Biosciences in a report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Castle Biosciences has an average rating of “Moderate Buy” and an average price target of $47.14.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. AIGH Capital Management LLC acquired a new stake in shares of Castle Biosciences in the third quarter valued at approximately $16,105,000. Braidwell LP raised its position in Castle Biosciences by 125.3% in the 2nd quarter. Braidwell LP now owns 822,735 shares of the company’s stock valued at $16,800,000 after purchasing an additional 457,488 shares during the last quarter. Summit Partners Public Asset Management LLC acquired a new stake in Castle Biosciences during the 3rd quarter worth $9,108,000. Millennium Management LLC boosted its stake in Castle Biosciences by 34.2% during the 3rd quarter. Millennium Management LLC now owns 575,089 shares of the company’s stock worth $13,095,000 after purchasing an additional 146,692 shares during the period. Finally, Bridgeway Capital Management LLC grew its position in Castle Biosciences by 334.8% during the 3rd quarter. Bridgeway Capital Management LLC now owns 177,180 shares of the company’s stock worth $4,034,000 after purchasing an additional 136,430 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.